EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Management of Acne Vulgaris With Trifarotene

Jerry Tan iD, Rajeev Chavda iD, Hilary Baldwin, Brigitte Dreno

Journal of Cutaneous Medicine and Surgery · 2023-07 · 27 (4) · 368-374

DOI: 10.1177/12034754231163542 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cutaneous Medicine and Surgery, online erschienen am 16.03.2023. Verfasst von Jerry Tan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Windsor Clinical Research Inc, Ontario, Canada. Hauptthemen laut MEDLINE: Dermatologic Agents, Acne Vulgaris. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Topical retinoids have an essential role in treatment of acne. Trifarotene, a topical retinoid selective for retinoic acid receptor (RAR) γ, is the most recent retinoid approved for treatment of acne. RAR-γ is the most common isoform of RARs in skin, and the strong selectivity of trifarotene for RAR-γ translates to efficacy in low concentration. Trifarotene, like other topical retinoids, acts by increasing keratinocyte differentiation and decreasing proliferation, which reduces hyperkeratinization. Retinoids have also been shown to inhibit inflammatory pathways via effects on leukocyte migration, toll-like receptors, and Activator Protein (AP)−1. Large-scale randomized, controlled clinical trials have demonstrated trifarotene to be safe, well tolerated, and efficacious in reducing both comedones and papules/pustules of acne. However, unlike all other retinoids, trifarotene is the first topical retinoid with rigorous clinical data on safety and efficacy in truncal acne. Data supporting use of trifarotene to manage acne are reviewed in this publication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatologic AgentsAcne VulgarisHumansAdministration, CutaneousRetinoids

Stichwörter der Autor:innen

Acne vulgarisfacial acnetopical retinoidstrifarotenetruncal acne

Substanzen

trifaroteneDermatologic AgentsRetinoids

Autor:innen und Institutionen

  • Windsor Clinical Research Inc, Ontario, Canada.
  • Department of Medicine, University of Western Ontario, Windsor Campus, Canada.
  • Galderma, Switzerland.
  • Robert Wood Johnson Medical Center, New Brunswick, New Jersey, USA.
  • The Acne Treatment and Research Center, Brooklyn, New York, USA.
  • Dermato-cancerology Department, CHU Nantes, University of Nantes, France.

ORCID-Profile: Jerry Tan, Rajeev Chavda

Zitieren

APA

Tan, J., Chavda, R., Baldwin, H., & Dreno, B. (2023). Management of Acne Vulgaris With Trifarotene. Journal of Cutaneous Medicine and Surgery, 27(4), 368-374. https://doi.org/10.1177/12034754231163542

Vancouver

Tan J, Chavda R, Baldwin H, Dreno B. Management of Acne Vulgaris With Trifarotene. Journal of Cutaneous Medicine and Surgery. 2023;27(4):368-374. doi:10.1177/12034754231163542

BibTeX
@article{Tan2023,
  author = {Tan, Jerry and Chavda, Rajeev and Baldwin, Hilary and Dreno, Brigitte},
  title = {Management of Acne Vulgaris With Trifarotene},
  journal = {Journal of Cutaneous Medicine and Surgery},
  year = {2023},
  volume = {27},
  number = {4},
  pages = {368--374},
  doi = {10.1177/12034754231163542}
}
Kostenlos starten →